

Author: Nikhil Kishore, PharmD Candidate 2023 Preceptor: Melanie Geer, PharmD, BCPS and Kyle Kojiro, PharmD, BCPS Date: December 2022

Introduction/Background

Albumin is the most abundant protein found in plasma in healthy individuals. Intravenous human albumin is used as a plasma expander in various critical conditions, due to its osmotic effect. Recently, the Becker's Hospital Review and ASHP Drug Shortage both identified that albumin 5% and 25% products were affected by a critical shortage worldwide. The limited availability makes it essential to define evidence-based criteria for the therapeutic use of albumin. The use of albumin can be indicated in acute conditions such as:

Ascites/Large Volume Paracentesis in patients with Cirrhosis

 A paracentesis volume > 5L can, in some cases, lead to hypovolemia and particularly unfavorable hemodynamic changes. Per the Association for the Study of Liver Diseases (AASLD) guidelines, post paracentesis albumin infusion may not be necessary for a single paracentesis of less than 4–5 L. However, for large-volume paracenteses, an albumin infusion of 6-8 g/L of fluid removed can be considered.

Spontaneous Bacterial Peritonitis

• A common and severe complication of ascitic cirrhosis, can be characterized by spontaneous infection of the ascitic fluid, in the absence of abdominal sources of infection. The AASLD guidelines recommend albumin should be given when the serum creatinine is >1 mg/dL, blood urea nitrogen >30 mg/dL, or total bilirubin >4 mg/dL, but is not necessary in patients who do not meet these criteria.

Hepatorenal Syndrome

 Hepatorenal syndrome consists of deterioration in renal function can be considered the extreme outcome of hemodynamic dysfunction of cirrhosis. The AASLD guidelines has a strong recommendation for albumin infusion plus administration of vasoactive drugs such as octreotide and midodrine in the treatment of type I hepatorenal syndrome. The guideline also recommends a two-day trial of albumin in the diagnosis of hepatorenal syndrome.

Plasmapheresis

The use of albumin is appropriate only for the exchange of large volumes of plasma: more than 20 mL/kg in a single session or 20 mL/kg/week in successive sessions. There are no clear guidelines on volume of 5% albumin should be infused. However, based on other institution guidelines, it is recommended to replace 70-80% of plasma volume removed. American Society for Apheresis (ASFA) guidelines suggest the use of albumin or fresh-frozen plasma based on the specific drug-binding affinities to help draw the medication into the intravascular space.

Cardiac Surgery

- Albumin can be used as a post-operative volume expander, as a last choice of treatment after crystalloids or non-protein colloids, following heart surgery. Crystalloids are the first choice for priming the circuitry in the case of extracorporeal circulation. In a systematic review by Haynes, G R et al., albumin administration in cardiac surgery resulted in lower fluid requirements, higher colloid oncotic pressure, reduced pulmonary edema with respiratory impairment and greater hemodilution compared with crystalloid and hydroxyethyl starch, which increased postoperative bleeding.
- A retrospective cohort study conducted by Dingankar, Adil R et al., provides evidence that the use of crystalloids for volume resuscitation after pediatric cardiac surgery is superior to 5% albumin. The use of crystalloids was associated with reduced fluid administration despite the theoretical oncotic advantage of albumin.

Intradialytic Hypotension

• According to the 2021 Clinical Journal of the American Society of Nephrology (CJASN), intravenous albumin may be administered to prevent or treat hypotension or to augment fluid removal, but this practice is controversial. In the 2004 Albumin versus Saline for the Treatment of Intradialytic Hypotension trial, it was concluded that 5% albumin is no more effective than normal saline for the treatment of IDH in chronic hemodialysis patients.

Pump Priming in Hemodialysis

• A retrospective study Skagerlind, Malin et al. suggests that using a heparin and albumin mixture minimized the risk of clotting and enabled acute intermittent hemodialysis in vulnerable patients without increased bleeding.

Organ Transplantation

• Albumin can be useful in the post-operative period following liver transplantation, to control the ascites and peripheral edema and to replace the loss of ascitic fluid through the drainage tubes.

Sepsis/Septic Shock

 Based on the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 (SSC), patients with sepsis induced hypoperfusion or septic shock should be given at least 30 mL/kg of IV crystalloid fluid within the first 3 hours of resuscitation. The guideline suggests using albumin after patients received large volumes of crystalloids with no clear cutoff value for crystalloid infusion.

Nephrotic Syndrome

• Patients with serum albumin < 2 g/dL, with hypovolemia and/or acute pulmonary edema and/or acute renal failure. The 2014 Japanese Society of Nephrology (JSN) suggests albumin administration does not improve hypoalbuminemia or edema in patients with nephrotic syndrome and may exacerbate hypertension. However, albumin administration may be useful in severe edema refectory to diuresis.

Thermal Injury (hypovolemia)

• Per Legacy Protocol, this is an approved indication. Albumin is considered second line and must need Burn Attending approval.

Acute Respiratory Distress Syndrome (ARDS)

• Albumin and furosemide therapy improves fluid balance, oxygenation, and hemodynamics in hypoproteinemia patients with acute lung injury, according to a clinical trial comparing albumin and furosemide versus dual placebo by Martin, Greg S et al.

<u>ECMO</u>

• The Extracorporeal Life Support Organization (ELSO) guidelines do not specify which fluid to use to rectify low flow states. A retrospective study of adult patients treated with venovenous or venoarterial ECMO receiving crystalloid or albumin boluses for volume resuscitation showed there were no noted benefits of colloid versus crystalloid administration on hemodynamic or ECMO fluid response.

Large Clinical Trials

Study	Major Findings
2004 Saline versus Albumin Fluid Evaluation (SAFE) trial	Trial randomized 6,997 ICU patients requiring IV fluids to either albumin or saline. There was no difference in all-cause mortality between the two groups.
2004 Albumin versus Saline for the Treatment of Intradialytic Hypotension trial	A randomized, double-blind, crossover trial was performed in 72 chronic hemodialysis patients to determine whether 5% albumin was more effective than normal saline for the treatment of intradialytic hypotension (IDH). It is concluded that 5% albumin is no more effective than normal saline for the treatment of IDH in chronic hemodialysis patients. Normal saline should be used as the initial fluid for the treatment of IDH.
2013 Colloids Versus Crystalloids for the Resuscitation of the Critically III (CRISTAL) trial	Trial randomized 2,857 ICU patients with hypovolemic shock, mostly with concurrent sepsis, to volume resuscitation with either colloids or crystalloids. There was no difference in the primary outcome of all- cause mortality at 28 days between the two groups, although colloids were associated with a reduction in the secondary outcome of all- cause mortality at 90 days.
2014 Albumin Italian Outcome Sepsis (ALBIOS) trial	Trial randomized 1,818 patients with severe sepsis or septic shock at 100 Italian ICUs in an unblinded fashion to albumin or no albumin. Both groups were treated with crystalloids as needed. There was no difference in all-cause mortality at 28 days and 90 days. There was no difference in overall Sequential Organ Failure Assessment (SOFA) scores between the two groups.
2022 Albumin in Cardiac Surgery (ALBICS) trial	Trial randomized 1,386 patients undergoing cardiac surgery with cardiopulmonary bypass. The results of this trial indicate that

Table 1: Select Studies Examining Albumin Utilization

treatment with 4% albumin solution for priming and perioperative
intravenous volume replacement compared with Ringer acetate did
not significantly reduce the risk of adverse events over the following
90 days among patients undergoing on-pump cardiac surgery.

Current Order Sets

- IP Hemodialysis Adult Procedure [1212]
- IP Cardiac Surgery Pediatric Postoperative [1310]
- IP Renal Replacement ICU Pediatric Add on [1388]
- IP Traumatic Brain Injury ICU- Pediatric Admission [2465]
- IP Apheresis Adult Procedure [745]
- IP Surgery Oregon Burn Center Adult Procedure [557]
- IP ECMO Adult Procedure [2084]
- IP Surgery Oregon Burn Center Adult Postoperative [2319]
- IP Hemodialysis Pediatric Procedure [2555]
- IP Apheresis Pediatric Procedure [2031]
- IP Cardiac Surgery Adult Postoperative [1616]

Objective

The albumin shortage provided an opportunity to evaluate the institutional pattern of albumin use across Legacy Health system using evidence-based criteria, to optimize albumin usage for only appropriate indications.

Methods

PowerBI was used to generate a report of all albumin administrations from September 13 and September 17, 2022. This retrospective, observational chart review study included patients that received at least one dose of albumin at Legacy Health during the study period. All de-identified data was collected including patient age, facility, department, hospital site, order set, date/time, dose, quantity, frequency, prescriber, and cost. A thorough chart review was conducted to evaluate indication of albumin use, dosing appropriateness and any alternative medication use. The collected data was then analyzed using descriptive statistics to characterize albumin use within the Legacy Health system. External database searches, guidelines from AASLD, ASFA, SSC and recommendations developed by other healthcare organizations were used to evaluate the appropriateness of albumin use.

Results

Figure 1: Albumin Administration by Indication September 1st – 30th 2022



Table 1: Albumin Administration by Order Set September 1st – 30th 2022

Order Set	Total Doses
No Order Set	570
Hemodialysis	104
Cardiac Surgery Postoperative	44
Peds Cardiac Surgery Postoperative	33
Large Volume Paracentesis	22
Oregon Burn Center Admission	14
Therapeutic Apheresis Procedure	13
IP Adult ECMO	11

Figure 2: Alternative treatment Tried first, for Select Indications (cardiac surgery, general surgery, intradialytic hypotension, organ transplantation, sepsis/septic shock, nephrotic syndrome, thermal injury, acute respiratory distress syndrome)



Discussion/Conclusion

Treatments requiring albumin should be considered only after failure of first line regimens for the respective indication and situation. The use of albumin should be assessed daily and should be discontinued as soon as therapy is no longer required according to monitored parameters. Information for the albumin use criteria was based on guidelines from AASLD, ASFA, SSC, clinical trials, and guidelines from other institutions (University of Wisconsin, Stanford, and Providence). Overall, continued evaluation of evidence-based criteria should be performed to examine institutional use patterns, to determine the impact on patient therapeutic outcomes, and to identify modifications needed. The drug shortage offered an opportunity for our health system to evaluate usage patterns and develop evidence-based usage criteria to ensure ongoing stewardship of a medication that may be overutilized.

Recommendations

	Indication	Guideline	Dose
\checkmark	Ascites/Large Volume Paracentesis in patients with Cirrhosis	1 st Line: Dietary sodium restriction (2 g/day) & oral diuretics 2 nd Line: Albumin (only if >5 liters of fluid removed)	Albumin 25%: 6-8 g/liter of ascitic fluid removed
\checkmark	Spontaneous Bacterial Peritonitis (SBP)	 Meets one of the following: 1. Serum creatine >1 mg/dL 2. Blood urea nitrogen >30 mg/dL Total bilirubin >4 mg/dL 	Albumin 25%: Day 1: 1.5 g/kg given within 6 hours of diagnosis (Max: 100 g) Day 3: 1 g/kg (Max: 100 g) Given in combination with antibiotic
\checkmark	Hepatorenal Syndrome (HRS) Type 1	 For diagnosis of suspected: Cirrhosis with ascites Serum creatine >1.5 mg/dL Confirmed: Serum creatine >1.5 mg/dL in presence of cirrhosis Absence of improvement in renal function after discontinuation of diuretics and trial of albumin 1 g/kg/day Absence of proteinuria (<500 mg/day) or hematuria (<50 red cells per high-power field) and/or abnormal renal ultrasonography Absence of shock No current or recent use of nephrotoxic drugs (NSAIDs, aminoglycosides, or iodinated contrast media) Non-ICU: Albumin + Octreotide + Midodrine ICU: Albumin + Norepinephrine 	 Albumin 25%: Diagnosis: 1 g/kg/day for 2 days (Max: 100g) Confirmed: 20-40 g/day Treatment can be continued until octreotide and midodrine are administered, or until adequate intravascular volume is achieved
\checkmark	Plasmapheresis	For large volume plasma exchange of greater than 20 mL/kg in one session or repeated sessions.*	Albumin 5%: Dose to plasma volume removed* (70-80%)
\checkmark	Cardiac Surgery Postoperative Volume Resuscitation	Adult Restrict albumin for patients requiring >2 liters of crystalloid in first 24 hours post-op of cardiac surgery 1 st Line: Crystalloid Last Line: Crystalloid + Albumin [after failure of crystalloid attempt and at the discretion of the physician]	Albumin 5%: 12.5 g every 1-hour PRN

	Intradialytic	Adult	Adult
	Hypotension	SBP decreased by \geq 10 mmgHG from initial blood	Albumin 25%:
		pressure OR SBP <90 or MAP <60 mmHg +/-	12.5 g or 25 g every 1-hour
		symptoms of hypotension	PRN
		 Ultrafiltration rate should be decreased or stopped Patient should be placed in the Trendelenburg position <i>IV bolus of 250 mL NS</i> Reassess BP and symptoms of hypotension If no resolution → <i>IV bolus of 250 mL NS</i> Reassess BP and symptoms of hypotension <i>Albumin 25%</i> Reassess BP and symptoms of hypotension If no resolution → <i>Albumin 25%</i> Contact nephrologist 	Pediatric Albumin 25% or 5% 5%: 10 mL/kg 25%: 0.5 g/kg
	Postoperative Liver	Control of ascites and peripheral edema if serum	Albumin 25%:
	Transplantation	albumin is <2.5 gm/dL with hematocrit >30%	25 g/day
·		<i></i>	с, ,
	Sepsis/Septic Shock	Adult	Adult
		It is recommended to use crystalloids as first line for	Albumin 5%:
		resuscitation. It is suggested to use albumin in	12.5 – 25 g
		patients who received large volumes of crystalloids	_
		1 st Line: Crystalloids – at least 30 mL/kg of IV	
		crystalloids should be given withing the first 3 hours	
		of resuscitation	
		Last Line: Albumin 5% - after failure of large volume	
		of crystalloids, 4-5 liters	
		<u>Pediatric</u>	<u>Pediatric</u>
		It is suggested to use crystalloids, rather than	Albumin 5%:
		albumin for the initial resuscitation of children with	5-10 mL/kg
		septic shock or other sepsis-associated organ	
		dysfunction	
		1 st Lines Crustellaide, up to 40 C0 rel /kg in balve	
		fluid (10.20 ml (kg par balus) ever the first baur	
		titrated to clinical markers of cardiac output and	
		discontinued if signs of fluid overload develop	
		Repeat if no improvement after first infusion	
		Last Line: Albumin 5%	
	Nephrotic Syndrome	Albumin <2 g/dL with hypovolemia and/or pulmonary	Albumin 25%:
		edema with loop diuretic resistance	25 g
		· · · · · · · · · · · · · · · · · · ·	5

			Pediatrics: 0.5-1 gm/kg/dose, maximum 25 g/dose (rounded to 12.5 or 25 gm). Maximum 2 doses in 24 hours. Given in combination with
	Thermal Injury	See OBC Fluid Resuscitation Protocol	Albumin 5%
	(hypovolemia)		
,		Albumin Protocol: 1 Current I.B. maintenance rate divided by 2 =	Per protocol - used 2 ¹¹⁶ line,
\checkmark		mLs/hr	
		2. Start Albumin 5% @ above rate	
		3. Reduce LR to above rate	
	Acute Respiratory	Patients with acute lung injury/acute respiratory	Albumin 25%:
	Distress Syndrome	distress syndrome, whose serum total protein	25 g every 8 hours as needed
\checkmark	(ARDS)	concentrations are <6.0 g/dL	for 3 days
			Given in combination with
			furosemide
	Extracorporeal	Utilize crystalloid first and alternate albumin and	Albumin 5%
V	Oxygenation (ECMO)		crystalloid
	Traumatic Brain Injury	Albumin administration is associated with increased	
Х	(TBI)	intracranial pressure, which led to increased	
	Trauma	Several trials show either no benefit, or in some	
		cases worse outcomes, with albumin thus making	
Х		this solution not recommended in the resuscitation	
		of trauma patients	
	Hypoalbuminemia	Little evidence to support practice of albumin	
Х		supplementation. Hypoalbuminemia in the absence	
	Malautritian	of edema or acute hypotension.	
x	wanutrition	inappropriate indication	

1. For <u>IP - Cardiac Surgery - Pediatric - Postoperative [1310]</u> order set:

- a. Add crystalloid as a first-line option for volume resuscitation
- 2. For <u>IP Cardiac Surgery Adult Postoperative [1616]</u> order set:
 - a. Add administration instructions to direct nursing staff to use crystalloids before albumin.

- 3. For IP Hemodialysis Adult Procedure [1212] & IP Hemodialysis Pediatric Procedure [2555] order sets:
 - a. Add crystalloids options to adult hemodialysis order set.
 - b. Implementation of an algorithm for the treatment of intradialytic hypotension for both adult and pediatric patients are needed to reduce albumin utilization.
- 4. For IP Apheresis Adult Procedure [745] order set:
 - a. Change 3,000 mL dose to a variable dose or ability to enter a specific dose.
- 5. For IP Traumatic Brain Injury ICU- Pediatric Admission [2465] order set:
 - a. Consider removal from the order set
- 6. Optimize ordering process in EPIC for all indications, either with order questions, an order panel, or an order set.

Stakeholder Input

Input received from:

Pharmacy Clinical Managers

- Dr. Nick Eshraghi
- Dr. Vikas Grover
- Dr. Andrew Tsen
- Dr. Marc LeGras
- Dr. James Kyser
- Bob Morris, Perfusionist
- Dr. Pasala Ravichandran
- Dr. Oliver Padgett

References

1. Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). Recommendations for the use of albumin and immunoglobulins. *Blood Transfus*. 2009;7(3):216-234. doi:10.2450/2009.0094-09

Acute Respiratory Distress Syndrome

 Uhlig C, Silva PL, Deckert S, Schmitt J, de Abreu MG. Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis. *Crit Care*. 2014;18(1):R10. Published 2014 Jan 9. doi:10.1186/cc13187

Ascites/Large Volume Paracentesis/SBP/HRS

3. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology*. 2009;49(6):2087-2107. doi:10.1002/hep.22853

Cardiac Surgery

- Dingankar AR, Cave DA, Anand V, et al. Albumin 5% Versus Crystalloids for Fluid Resuscitation in Children After Cardiac Surgery. *Pediatric Crit Care Med*. 2018;19(9):846-853. doi:10.1097/PCC.00000000001657
- Rabin J, Meyenburg T, Lowery AV, Rouse M, Gammie JS, Herr D. Restricted Albumin Utilization Is Safe and Cost Effective in a Cardiac Surgery Intensive Care Unit. *Ann Thorac Surg.* 2017;104(1):42-48. doi:10.1016/j.athoracsur.2016.10.018
- Hanley C, Callum J, Karkouti K, Bartoszko J. Albumin in adult cardiac surgery: a narrative review. L'albumine en chirurgie cardiaque adulte : un compte rendu narratif. *Can J Anaesth*. 2021;68(8):1197-1213. doi:10.1007/s12630-021-01991-7
- 7. Vlasov H, Juvonen T, Hiippala S, et al. Effect and safety of 4% albumin in the treatment of cardiac surgery patients: study protocol for the randomized, double-blind, clinical ALBICS (ALBumin In Cardiac Surgery) trial. *Trials*. 2020;21(1):235. Published 2020 Feb 28. doi:10.1186/s13063-020-4160-3
- Haynes GR, Navickis RJ, Wilkes MM. Albumin administration--what is the evidence of clinical benefit? A systematic review of randomized controlled trials. *Eur J Anaesthesiol*. 2003;20(10):771-793. doi:10.1017/s0265021503001273

<u>ECMO</u>

 Bridges BC, Dhar A, Ramanathan K, Steflik HJ, Schmidt M, Shekar K. Extracorporeal Life Support Organization Guidelines for Fluid Overload, Acute Kidney Injury, and Electrolyte Management. ASAIO J. 2022;68(5):611-618. doi:10.1097/MAT.000000000001702

Fluid Resuscitation

- SAFE Study Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australian Red Cross Blood Service; Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007;357(9):874-884. doi:10.1056/NEJMoa067514
- 11. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med*. 2004;350(22):2247-2256. doi:10.1056/NEJMoa040232
- Annane D, Siami S, Jaber S, et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial [published correction appears in JAMA. 2013 Mar 12;311(10):1071. Régnier, Jean [corrected to Reignier, Jean]; Cle'h, Christophe [corrected to Clec'h, Christophe]]. JAMA. 2013;310(17):1809-1817. doi:10.1001/jama.2013.280502
- Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. *Cochrane Database Syst Rev.* 2004;(4):CD001208. Published 2004 Oct 18. doi:10.1002/14651858.CD001208.pub2
- 14. Wise R, Faurie M, Malbrain MLNG, Hodgson E. Strategies for Intravenous Fluid Resuscitation in Trauma Patients. *World J Surg.* 2017;41(5):1170-1183. doi:10.1007/s00268-016-3865-7

Intradialytic Hypotension

- Hryciw N, Joannidis M, Hiremath S, Callum J, Clark EG. Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration during Kidney Replacement Therapy. *Clin J Am Soc Nephrol*. 2021;16(5):820-828. doi:10.2215/CJN.09670620
- Emili S, Black NA, Paul RV, Rexing CJ, Ullian ME. A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients. *Am J Kidney Dis*. 1999;33(6):1107-1114. doi:10.1016/S0272-6386(99)70148-4

- Yin L, Dubovetsky D, Louzon-Lynch P. Implementation of an Algorithm Utilizing Saline Versus Albumin for the Treatment of Intradialytic Hypotension. *Ann Pharmacother*. 2019;53(2):159-164. doi:10.1177/1060028018801024
- Knoll GA, Grabowski JA, Dervin GF, O'Rourke K. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. *J Am Soc Nephrol*. 2004;15(2):487-492. doi:10.1097/01.asn.0000108971.98071.f2

Nephrotic Syndrome

- 19. Nishi S, Ubara Y, Utsunomiya Y, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. *Clin Exp Nephrol*. 2016;20(3):342-370. doi:10.1007/s10157-015-1216-x
- 20. Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. *Crit Care Med*. 2002;30(10):2175-2182. doi:10.1097/00003246-200210000-00001

Plasmapheresis

21. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. *J Clin Apher*. 2016;31(3):149-162. doi:10.1002/jca.21470

<u>Priming</u>

- 22. Skagerlind M, Stegmayr B. Heparin albumin priming in a clinical setting for hemodialysis patients at risk for bleeding. *Hemodial Int*. 2017;21(2):180-189. doi:10.1111/hdi.12472
- 23. Russell JA, Navickis RJ, Wilkes MM. Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. *J Cardiothorac Vasc Anesth*. 2004;18(4):429-437. doi:10.1053/j.jvca.2004.05.019

Sepsis/Septic Shock

- 24. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Crit Care Med*. 2021;49(11):e1063-e1143. doi:10.1097/CCM.00000000005337
- 25. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. *Pediatric Crit Care Med.* 2020;21(2):e52-e106. doi:10.1097/PCC.00000000002198

Order Sets:

IP - Hemodialysis - Adult - Procedure [1212]

Medications

inedications Dialys	is
lidocaine injection	n PF 10 mg/mL (1%)
1 mL, IntraDermal, C	DNCE PRN, Other, prior to graft/fistula needle insertion
Heparin (MINI) Bo	olus and Drip - For use in dialysis pump for Graft/Fistula
1,000 Units, IntraVer	nous, PRN, For use in dialysis pump. Mini = 1000 unit bolus then 500 units/hour - stop 1 hour before end of dialysis. FOR DIALYSIS ONLY
albumin human 5	i % bottle - To prime dialysis pump.
12.5 g, Extracorpore	al, ONCE, To prime dialysis pump. FOR DIALYSIS ONLY
albumin human 2	25 % infusion
12.5 g, IntraVenous,	EVERY 1 HOUR PRN, SBP less than*** or DBP less than*** during dialysis. FOR DIALYSIS ONLY, Other, for blood pressure support during dialysi
mannitol 25 % inj	jection
12.5 g, IntraVenous,	EVERY 1 HOUR PRN, for signs/symptoms of dialysis disequilibrium syndrome during dialysis, FOR DIALYSIS ONLY
heparin lock injec	t ion 1000 units/mL E AFTER DIALYSIS, Lock dialysis catheter after each dialysis. FOR DIALYSIS ONLY
heparin (PF) 100 u	units/mL syringe
Intra-Catheter, ONC	E AFTER DIALYSIS, Lock dialysis catheter after each dialysis. FOR DIALYSIS ONLY
sodium citrate so	lution 4% - lock dialysis catheter after each dialysis ①
Dialysis, ONCE AFTE	R DIALYSIS, Lock dialysis catheter after each dialysis. FOR DIALYSIS ONLY
epoetin alfa-epbx	د (Retacrit) injection
IntraVenous, ONCE	AFTER DIALYSIS
alteplase (CATHFI	LO ACTIVASE) injection
4 mg, Intra-Catheter	r, ONCE PRN, To declot RED port of dialysis catheter, FOR DIALYSIS ONLY
alteplase (CATHFI	LO ACTIVASE) injection
4 mg, Intra-Catheter	r, ONCE PRN, To declot BLUE port of dialysis catheter, FOR DIALYSIS ONLY
paricalcitol (ZEMF	PLAR) injection
4 mcg, IntraVenous,	ONCE IN DIALYSIS, FOR DIALYSIS ONLY
iron sucrose (VEN	

▼IV Fluids ▼ IV Fluids & Albumin: Age >6 months Pediatric Maintenance IV Fluid (4-2-1 rule) albumin human 5 % bottle 10 mL/kg (Dosing Weight) 10 mL/kg, IntraVenous, PRN, Starting today at 0921, Until Discontinued, Post-op For poor perfusion/ SBP < *** and CVP < *** Other, Poor perfusion, Sign and Hold (i) albumin human 1 Frequency of 288 doses/day exceeds recommended maximum of 6 doses/day Missing Weight for dose checking heparin (PF) 500 Units in sodium chloride 0.9 % (NORMAL SALINE) 500 mL infusion Intra-Catheter, TITRATED, Starting today at 0945, Until Discontinued, Post-op, Sign and Hold sodium chloride 0.9 % (NORMAL SALINE FLUSH) injection 1 mL, EVERY 8 HOURS, Post-op Total Fluids Rate Routine, UNTIL DISCONTINUED, Total Fluids Rate ***, Post-op Use air filters on all IVs except pressure lines Routine, UNTIL DISCONTINUED, Use air filters on all IVs except pressure lines, Post-op ▼ Diuretics/Urinary Output furosemide (LASIX) injection 1 mg/kg, IntraVenous, EVERY 6 HOURS, Post-op, Start 6 hours post-op

albumin human 5 % bottle

10 mL/kg, IntraVenous, PRN, Post-op, Other, urine output less than 1mL/kg/hour and CVP less than ***

IP - Renal Replacement - ICU - Pediatric - Add on [1388]



Nursing Communication - Prime with blood (children less than 10 kg) ONE TIME, Additional prime with blood before starting CRRT

IP - Traumatic Brain Injury - ICU- Pediatric - Admission [2465]

▼ IV Fluids NS bolus us ONCE Maximum: 1000 ml 🗌 albumin human 5 % bottle mL/kg, IntraVer D5 LR + KCI 20 mEq/1000 mL (premix) D5 NS + KCl 20 mEq/1000 mL (premix) LR 1000 mL + KCI 20 mEq NS + KCI 20 mEq (premix) heparin (PF) 500 units in 0.9% sodium chloride 500 mL (Arterial Line)

heparin (PF) 500 units in 0.9% sodium chloride 500 mL (Central Line)

IP - Apheresis - Adult - Procedure [745]

Medications

Medications - Apheresis Procedure

citrate dextrose (ACD) A solution 1,000 mL, Intra-Catheter, ONCE, 1 dose, today at 1000 For apheresis procedure

0.9% NaCl (premix)

1,000 mL, IntraVenous, CONTINUOUS, Starting today at 1000, Until today at 1759 For prime and rinse back during apheresis procedure. Bolus 200 mL prn for low blood pressure according to parameters.

calcium infusion

Calcium gluconate in sodium chloride 0.9 % IVPB

IntraVenous, ONCE, The calcium dose is based on the total volume of replacement fluid ordered. For calcium gluconate, order 1 gm for every 1 liter of replacement fluid. Infuse over duration of procedure.

Calcium chloride in sodium chloride 0.9% IVPB

IntraVenous, ONCE, The calcium dose is based on the total volume of replacement fluid ordered. For calcium chloride, order 0.5 gm for every 1 liter of replacement fluid. Infuse over duration of procedure.

albumin human 5 % bottle

3,000 mL, IntraVenous, ONCE, For apheresis procedure

☐ IP MED DIPHENHYDRAMINE IV OR PO PANEL

acetaminophen (TYLENOL) tablet

650 mg, Oral, ONCE, Give 30 minutes prior to apheresis. Maximum dose of acetaminophen is 4000 mg from all sources in 24 hours.

methylPREDNISolone (Solu-MEDROL) IV

40 mg, IntraVenous, ONCE PRN, Other, for reaction to apheresis procedure

IP - Surgery - Oregon Burn Center - Adult - Procedure [557]

▼IV Fluids

- OBC Fluid Resuscitation
- Follow OBC Fluid Resuscitation Protocol UNTIL DISCONTINUED
- □ lactated ringers infusion Adults 1,000 mL, IntraVenous, TITRATED, Follow OBC resuscitation protocol. Maintenance fluid goal = *** ml/hr.
- albumin human 5 % bottle IntraVenous, CONTINUOUS, Follow OBC resuscitation protocol. Titrate LR and albumin together 1:1 per protocol.
- lactated ringers infusion 1,000 mL, IntraVenous, CONTINUOUS

IP - ECMO - Adult - Procedure [2084]

	V-	an article and Velume Management
٢.	va	isoactives and volume management
	~	norepinephrine in 0.9% NaCI (Levophed) 32 mcg/mL 250 mL CENTRAL infusion premix 0-3 mcg/kg/min, IntraVenous, TITRATED, Starting today at 1000, Until Discontinued Initiate infusion at 0.05 mcg/kg/min. Titrate by 0.03 mcg/kg/min every 5 minutes to achieve MAP 65+.
		 Torepinephrine Missing Weight for dose checking
	~	albumin human 5 % bottle 12.5-25 g 12.5-25 g, IntraVenous, EVERY 1 HOUR PRN, Starting today at 0939, Until Discontinued For hypotension, administer as bolus over 5-10 minutes; for all other indications, infuse over 1-2 hours Other, For ECMO venous chatter
		 Ibumin human Daily dose of 300-600 g (12.5-25 g EVERY 1 HOUR PRN) exceeds recommended maximum of 125 g by 380% Frequency of 24 doses/day exceeds recommended maximum of 6 doses/day Missing Weight for dose checking
	~	metoprolol (LOPRESSOR) injection 2.5-5 mg 2.5-5 mg, IntraVenous, EVERY 5 MIN PRN, Starting today at 0939, Until Discontinued, Other, for HR > 100 bpm. Hold if MAP < 65 mmHg or requiring >0.1 of norepinephrine or HR < 60 beats/min.

IP - Surgery - Oregon Burn Center - Adult - Postoperative [2319]

▼IV Fluids

- OBC Fluid Protocol
- 🗌 albumin human 5 % bottle
- IntraVenous, CONTINUOUS, Post-op, Follow OBC resuscitation protocol. Titrate LR and albumin together 1:1 per protocol.
- Iactated ringers infusion 1,000 mL, IntraVenous, CONTINUOUS, Post-op

IP - Apheresis - Pediatric - Procedure [2031]

Priming 0.9% NaCl (premix) Extracorporeal, Administer per apheresis circuit Albumin for children 10-20 kg Nursing Communication - Prime with blood for children less than 10 kg Prime with blood (children less than 10 kg) One time additional prime with start of apheresis Nursing Communication - Rinseback Blood Prime Nursing Communication - DO NOT Rinseback Blood Prime

IP - Hemodialysis - Pediatric - Procedure [2555]

▼ Medications

✓ Dialyzer Priming ○ 0.9% NaCI (NORMAL SALINE) infusion

1,000 mL, Extracorporeal, ONCE, To prime dialysis pump. FOR DIALYSIS ONLY

albumin human 5 % bottle

12.5 g, Extracorporeal, ONCE, To prime dialysis pump. FOR DIALYSIS ONLY

Neonatal Prepare and Transfuse Exchange RBC

Heparinzation

- heparin (PF) 100 Units/mL in sodium chloride 0.9 % (PF) 50 mL IV Syringe IntraVenous, CONTINUOUS, Starting today at 1000, Until Discontinued Administer during dialysis only
 - 5-25 Units/kg/hr

Blood Pressure Support

albumin human 5 % 10 mL/kg, IntraVenous, EVERY 1 HOUR PRN, SBP less than *** or DBP less than *** during dialysis. FOR DIALYSIS ONLY, Other, blood pressure support

albumin human 25 %

0.5 g/kg, IntraVenous, EVERY 1 HOUR PRN, SBP less than*** or DBP less than*** during dialysis. FOR DIALYSIS ONLY, Other, blood pressure support

NS bolus

IntraVenous, CONTINUOUS PRN, Other, Blood pressure support

mannitol 25 % injection

12.5 g, IntraVenous, EVERY 1 HOUR PRN, for signs/symptoms of dialysis disequilibrium syndrome during dialysis, FOR DIALYSIS ONLY

IP - Cardiac Surgery - Adult - Postoperative [1616]

▼ Fluid Management

LR (premix)

500 mL, at 1,000 mL/hr, IntraVenous, EVERY 1 HOUR PRN, Starting today at 0947, Until Discontinued, Administer over 30 Minutes, Post-op Alternate LR 500 mL with Albumin 5% 250 mL. Notify LIP when the total of LR and Albumin equal 2000 mL Other, Per protocol, Sign and Hold

albumin human 5 % bottle 12.5 g

2.5 g, IntraVenous, EVERY 1 HOUR PRN, Starting today at 0947, Until Discontinued, Post-op Alternate LR 500 mL with Albumin 5% 250 mL. Notify LIP when the total of LR and Albumin equal 2000 mL. Other, Per protocol, Sign and Hold

(1) albumin human

- 1 Daily dose of 300 g (12.5 g EVERY 1 HOUR PRN) exceeds recommended maximum of 125 g by 140%
- 1 Frequency of 24 doses/day exceeds recommended maximum of 6 doses/day
- Missing Weight for dose checking